½ÃÀ庸°í¼­
»óǰÄÚµå
1573707

¼¼°èÀÇ Áø´Ü¿ë ÀΰøÁö´É(AI) ½ÃÀå : ½ÃÀå µ¿Çâ, ¼ºÀå ÃËÁø¿äÀÎ, »ê¾÷ µ¿Ç⠺м®°ú ¿¹Ãø(2024-2032³â)

Artificial Intelligence in Diagnostics Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Global Market Insights Inc. | ÆäÀÌÁö Á¤º¸: ¿µ¹® 100 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

Áø´Ü¿ë ÀΰøÁö´É ¼¼°è ½ÃÀå ±Ô¸ð´Â 2023³â¿¡ 11¾ï ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù.

¿¹ÃøÀº ¸¸¼º ÁúȯÀÇ À¯º´·ü »ó½Â°ú Áúº´ Áø´Ü¿¡¼­ AI µµ±¸ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó 2024³âºÎÅÍ 2032³â±îÁöÀÇ ¿¹»ó CAGRÀº 22.2%·Î °ßÁ¶ÇÑ ¼ºÀå ±Ëµµ¸¦ ³ªÅ¸³Â½À´Ï´Ù.

¸¸¼º ÁúȯÀÌ ¸¸¿¬ÇÔ¿¡ µû¶ó °Ç°­ °ü¸® Á¦°ø¾÷ü´Â Á¡Á¡ AI ¼Ö·ç¼ÇÀ» ÇâÇØ ³ª¾Æ°¡°í ÀÖ½À´Ï´Ù. ÀÌ µµ±¸´Â Á¶±â ¹ß°ßÀ» °­È­Çϰí Á¤È®ÇÑ Áø´ÜÀ» º¸ÀåÇÏ¸ç ´ç´¢º´°ú ¾Ï°ú °°Àº Áúº´¿¡ ´ëÇÑ ¸ÂÃãÇü Ä¡·á Àü·«À» ÃËÁøÇÕ´Ï´Ù. Àα¸ÀÇ °í·ÉÈ­, ¾É±â ½¬¿î ¶óÀÌÇÁ ½ºÅ¸ÀÏ, ½Ä»ýȰÀÇ È¥¶õ µîÀÇ ¿äÀÎÀÌ ¸¸¼º Áúȯ Áõ°¡¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ·Î ÀÎÇØ ´ë»ó Àα¸°¡ Å©°Ô Áõ°¡ÇÏ°í °Ç°­ °ü¸® ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¼¼°èº¸°Ç±â±¸(WHO)´Â 2023³â ¸¸¼ºÁúȯÀÌ ¼¼°è »çÀÎÀÇ 71%¸¦ Â÷ÁöÇÏ°í ½ÉÇ÷°üÁúȯ¸¸À¸·Î ¿¬°£ 1790¸¸ ¸íÀÌ »ç¸ÁÇϰí ÀÖ´Ù°í º¸°íÇß½À´Ï´Ù.

AI µµ±¸¿¡ ´ëÇÑ ¼ö¿ä´Â Áø´Ü¿ë AI ½ÃÀåÀÇ ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÀÇ·á ½Ã¼³Àº Áø´Ü Á¤È®µµ Çâ»ó, ¾÷¹« È¿À²¼º ¹× ȯÀÚ °á°ú °³¼±À» ¿ì¼±ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ¼ö¿ä´Â ÀÇ·á µ¥ÀÌÅÍÀÇ º¹À⼺, º¸´Ù ºü¸£°í ½Å·ÚÇÒ ¼ö ÀÖ´Â Áø´Ü ÇÁ·Î¼¼½ºÀÇ Çʿ伺, °³ÀÎÈ­µÈ ÀÇ·á¿¡ ´ëÇÑ °ü½É Áõ°¡·Î ÀÎÇÑ °ÍÀÔ´Ï´Ù. ¶ÇÇÑ AI ±â¼úÀÇ ±Þ¼ÓÇÑ ¹ßÀü°ú µðÁöÅÐ °Ç°­ °ü¸® Ç÷§ÆûÀÇ º¸±ÞÀº ´Ù¾çÇÑ Áø´Ü¿ë AI µµ±¸ÀÇ ÅëÇÕÀ» °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù.

2023³â¿¡´Â ¹æ»ç¼± ºÐ¾ß°¡ 28.4%ÀÇ ¼öÀÍ Á¡À¯À²·Î ½ÃÀåÀ» ¼±µµÇß½À´Ï´Ù. ¿¢½º·¹ÀÌ, CT ½ºÄµ, MRI, ÃÊÀ½ÆÄ °Ë»ç µî ¾öû³­ ÀÇ·á ¿µ»ó ºÐ¼®À» Æ÷ÇÔÇÑ ¹æ»ç¼±ÇÐÀº AI µµ±¸¶ó´Â À¯·ÂÇÑ ¾Æ±ºÀ» ¹ß°ßÇß½À´Ï´Ù. ÀÌ·¯ÇÑ µµ±¸´Â ÀÇ·á ¿µ»ó ó¸® ¹× ÇØ¼®ÀÌ ¿ì¼öÇϸç Áø´Ü È¿À²À» Å©°Ô Çâ»ó½Ãŵ´Ï´Ù. ¹æ»ç¼±ÇÐÀº ƯÈ÷ À̹ÌÁö Àνİú ÇØ¼®¿¡¼­ AI¸¦ µµÀÔÇÑ ÃÖÃÊÀÇ ÀÇ·á ºÐ¾ß Áß ÇϳªÀÔ´Ï´Ù. ÀÌ Á¶±â µµÀÔÀ¸·Î ¼º¼÷Çϰí Á¤±³ÇÑ AI µµ±¸°¡ ź»ýÇÏ¿© ÇöÀç´Â ÀÇ·á ½Ã¼³ Àüü¿¡¼­ ³Î¸® ½Å·ÚµÇ°í ÀÖÀ¸¸ç, ÀÌ ºÐ¾ßÀÇ ¼ºÀåÀ» °ßÀÎÇϰí ÀÖ½À´Ï´Ù.

º´¿ø ¹× Ŭ¸®´Ð ºÎ¹®Àº 2032³â±îÁö 33¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±¤´ëÇÏ°í ´Ù¾çÇÑ È¯ÀÚÃþÀ» º¸À¯ÇÑ º´¿ø ¹× Áø·á¼Ò´Â ±¤¹üÀ§ÇÑ Áø´Ü ¼­ºñ½º°¡ ÇÊ¿äÇÕ´Ï´Ù. ÀΰøÁö´ÉÀÌÀÖ´Â Áø´Ü µµ±¸´Â ¿µ»ó Áø´Ü¿¡¼­ ½ÇÇè½Ç °Ë»ç¿¡ À̸£±â±îÁö ´ë·®ÀÇ ÀýÂ÷¸¦ °ü¸®ÇÏ°í ½Å¼ÓÇϰí Á¤È®ÇÑ °á°ú¸¦ º¸ÀåÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ»ÇÕ´Ï´Ù. ÷´Ü ÀÇ·á±â¼ú µµÀÔÀÇ ÃÖÀü¼±¿¡ ÀÖ´Â º´¿ø ¹× Áø·á¼Ò´Â ÀÚ¿ø°ú ÀÎÇÁ¶ó¸¦ Ȱ¿ëÇÏ¿© °¢ ºÎ¹®ÀÇ AI ½Ã½ºÅÛÀ» ¿øÈ°ÇÏ°Ô ÅëÇÕÇϰí Áø´Ü ´É·ÂÀ» ³ôÀ̰í ȯÀÚ Äɾ Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù.

2023³â ºÏ¹ÌÀÇ AI Áø´Ü »ê¾÷Àº 4¾ï 5,160¸¸ ´Þ·¯¸¦ Â÷ÁöÇßÀ¸¸ç, 2024³âºÎÅÍ 2032³â±îÁöÀÇ CAGRÀº 21.2%·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù. ¹Ì±¹Àº ÃÖ÷´Ü °Ç°­ °ü¸® ±â¼úÀ» µµÀÔÇÏ´Â ¼±µÎ ÁÖÀÚÀÔ´Ï´Ù. ÀÌ Áö¿ªÀÇ ÀÇ·á ¼­ºñ½º Á¦°ø¾÷ü´Â Á¤È®¼ºÀ» ³ôÀÌ°í ¿À·ù¸¦ ÃÖ¼ÒÈ­Çϸç ȯÀÚ °á°ú¸¦ Çâ»ó½Ã۱â À§ÇØ AI ÁÖµµ Áø´Ü µµ±¸¸¦ äÅÃÇϱ⸦ ÀÇÁöÇÕ´Ï´Ù. ÀÌ µ¿ÇâÀº ±â¼ú Çõ½ÅÀ» Áß½ÃÇϰí, ÇコÄɾî ÀÎÇÁ¶ó°¡ È®°íÇÏ´Ù´Â °ÍÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ½ÉÇ÷°ü Áúȯ, ´ç´¢º´, ¾Ï µîÀÇ ¸¸¼º ÁúȯÀÇ À¯º´·üÀÌ ³ô±â ¶§¹®¿¡ ÀÌ Áö¿ª¿¡¼­´Â Á¶±â ¹ß°ß¡¤Á¶±â °ü¸®¿¡ À־ AI ±â¹ÝÀÇ Áø´ÜÀÇ ±ØÈ÷ Áß¿äÇÑ ¿ªÇÒÀÌ Àνĵǰí ÀÖ¾î ÇコÄɾ À־ AI ¼Ö·ç¼Ç ¼ö¿ä°¡ ´õ¿í ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú Á¶»ç ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ¾÷°è ÀλçÀÌÆ®

  • »ýÅÂ°è ºÐ¼®
  • ¾÷°è¿¡ ¹ÌÄ¡´Â ¿µÇâ¿äÀÎ
    • ¼ºÀå ÃËÁø¿äÀÎ
      • ¸¸¼º Áúȯ Áõ°¡
      • AI Åø¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡
      • ±â¼úÀÇ Áøº¸
      • À¯¸®ÇÑ Á¤ºÎÀÇ ´ëó¿Í ÀÚ±Ý Á¶´Þ
    • ¾÷°èÀÇ ÀáÀçÀû À§Çè ¹× °úÁ¦
      • ³ôÀº Á¶´Þ ºñ¿ë°ú À¯Áö º¸¼ö ºñ¿ë
      • µ¥ÀÌÅÍ ÇÁ¶óÀ̹ö½Ã¿Í º¸¾È¿¡ ´ëÇÑ ¿ì·Á
  • ¼ºÀå °¡´É¼º ºÐ¼®
  • ±ÔÁ¦ »óȲ
  • ±â¼ú »óȲ
  • ½ºÅ¸Æ®¾÷ ½Ã³ª¸®¿À
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
  • Àå·¡ ½ÃÀå µ¿Çâ
  • °¸ ºÐ¼®

Á¦4Àå °æÀï ±¸µµ

  • ¼Ò°³
  • ±â¾÷ ¸ÅÆ®¸¯½º ºÐ¼®
  • ÁÖ¿ä ±â¾÷ÀÇ °æÀï ºÐ¼®
  • °æÀï Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º
  • Àü·« ´ë½Ãº¸µå

Á¦5Àå ½ÃÀå Ãß°è ¹× ¿¹Ãø : ÄÄÆ÷³ÍÆ®º°, 2021-2032³â

  • ÁÖ¿ä µ¿Çâ
  • ¼ÒÇÁÆ®¿þ¾î
  • ¼­ºñ½º
  • Çϵå¿þ¾î

Á¦6Àå ½ÃÀå Ãß°è ¹× ¿¹Ãø : ¿ëµµº°, 2021-2032³â

  • ÁÖ¿ä µ¿Çâ
  • ¹æ»ç¼±
  • Á¾¾çÇÐ
  • ¼øÈ¯±â
  • ½Å°æÇÐ
  • º´¸®ÇÐ
  • °¨¿°ÁõÇÐ
  • ±âŸ ¿ëµµ

Á¦7Àå ½ÃÀå Ãß°è ¹× ¿¹Ãø : ¿ëµµº°, 2021-2032³â

  • ÁÖ¿ä µ¿Çâ
  • º´¿ø ¹× Áø·á¼Ò
  • Áø´Ü ½ÇÇè½Ç
  • À̹Ì¡ ¼¾ÅÍ
  • ±âŸ ÃÖÁ¾ »ç¿ëÀÚ

Á¦8Àå ½ÃÀå Ãß°è ¹× ¿¹Ãø : Áö¿ªº°, 2021-2032³â

  • ÁÖ¿ä µ¿Çâ
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ÀÌÅ»¸®¾Æ
    • ³×´ú¶õµå
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • È£ÁÖ
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ¾Æ¸£ÇîÆ¼³ª
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ³²¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦9Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ

  • Aidoc
  • AliveCor Inc.
  • Digital Diagnostics, Inc.
  • Enlitic
  • IBM Corporation
  • Imagen Technologies
  • NVIDIA Corporation
  • PathAI
  • RADLogics
  • Riverain Technologies
  • Siemens Healthineers
  • Sophia Genetics
  • Tempus
  • Vuno, Inc.
  • Zebra Medical Vision, Inc.
JHS 24.11.06

The Global Artificial Intelligence in Diagnostics Market was valued at USD 1.1 billion in 2023. Projections indicate a robust growth trajectory, with an expected CAGR of 22.2% from 2024 to 2032, due to the rising prevalence of chronic diseases and the growing demand for AI tools in disease diagnosis.

As chronic diseases become more prevalent, healthcare providers increasingly turn to AI solutions. These tools enhance early detection, ensure precise diagnoses, and facilitate tailored treatment strategies for conditions like diabetes and cancer. Factors such as an aging population, sedentary lifestyles, and poor dietary habits have fueled the rise in chronic conditions. This has led to a significant increase in the target population and heightened healthcare demand. The World Health Organization (WHO) reported in 2023 that chronic diseases are responsible for 71% of global deaths, with cardiovascular diseases alone accounting for 17.9 million fatalities annually.

The demand for AI tools is further propelling the growth of the AI in diagnostics market. Healthcare facilities prioritize enhanced diagnostic precision, operational efficiency, and improved patient outcomes. This demand stems from the growing complexity of medical data, the need for faster and more reliable diagnostic processes, and an intensified focus on personalized medicine. Moreover, swift advancements in AI technologies and the widespread adoption of digital healthcare platforms are hastening the integration of AI tools across various diagnostic applications.

The overall AI in diagnostic industry is segmented based on component, application, end-use, and region.

In 2023, the radiology segment led the market with a revenue share of 28.4%. Radiology, which encompasses the analysis of vast amounts of medical images like X-rays, CT scans, MRIs, and ultrasounds, has found a prime ally in AI tools. These tools excel in handling and interpreting medical images, significantly boosting diagnostic efficiency. Radiology was among the first medical domains to embrace AI, especially in image recognition and interpretation. This early adoption has resulted in mature and refined AI tools, now widely trusted across healthcare facilities, driving the segment's growth.

The hospitals and clinics segment is projected to reach USD 3.3 billion by 2032. Given their vast and diverse patient base, hospitals and clinics require a broad spectrum of diagnostic services. AI-powered diagnostic tools play a pivotal role in managing the high volume of procedures, from imaging to lab tests, ensuring swift and accurate results. Being at the forefront of adopting advanced medical technologies, hospitals and clinics leverage their resources and infrastructure to seamlessly integrate AI systems across departments, enhancing diagnostic capabilities and elevating patient care.

In 2023, North America AI in diagnostics industry accounted for USD 451.6 million, with projections indicating a CAGR of 21.2% from 2024 to 2032. The U.S. stands out as a leader in embracing state-of-the-art healthcare technologies. Healthcare providers in the region are eager to adopt AI-driven diagnostic tools, aiming to boost accuracy, minimize errors, and enhance patient outcomes. This trend is bolstered by a robust emphasis on technological innovation and a solid healthcare infrastructure. Furthermore, with a high prevalence of chronic diseases like cardiovascular issues, diabetes, and cancer, the region recognizes the pivotal role of AI-based diagnostics in early detection and management, further fueling the demand for AI solutions in healthcare.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates and calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising prevalence of chronic diseases
      • 3.2.1.2 Increasing demand for AI tools
      • 3.2.1.3 Technological advancements
      • 3.2.1.4 Favorable government initiatives and funding
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 High procurement and maintenance costs
      • 3.2.2.2 Data privacy and security concerns
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Technology landscape
  • 3.6 Start-up scenario
  • 3.7 Porter's analysis
  • 3.8 PESTEL analysis
  • 3.9 Future market trends
  • 3.10 Gap analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Competitive analysis of major key players
  • 4.4 Competitive positioning matrix
  • 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Component, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Software
  • 5.3 Services
  • 5.4 Hardware

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Radiology
  • 6.3 Oncology
  • 6.4 Cardiology
  • 6.5 Neurology
  • 6.6 Pathology
  • 6.7 Infectious diseases
  • 6.8 Other applications

Chapter 7 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Hospitals and clinics
  • 7.3 Diagnostic laboratories
  • 7.4 Imaging centers
  • 7.5 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 France
    • 8.3.4 Spain
    • 8.3.5 Italy
    • 8.3.6 Netherlands
    • 8.3.7 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 South Korea
    • 8.4.6 Rest of Asia Pacific
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Mexico
    • 8.5.3 Argentina
    • 8.5.4 Rest of Latin America
  • 8.6 Middle East and Africa
    • 8.6.1 South Africa
    • 8.6.2 Saudi Arabia
    • 8.6.3 UAE
    • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

  • 9.1 Aidoc
  • 9.2 AliveCor Inc.
  • 9.3 Digital Diagnostics, Inc.
  • 9.4 Enlitic
  • 9.5 IBM Corporation
  • 9.6 Imagen Technologies
  • 9.7 NVIDIA Corporation
  • 9.8 PathAI
  • 9.9 RADLogics
  • 9.10 Riverain Technologies
  • 9.11 Siemens Healthineers
  • 9.12 Sophia Genetics
  • 9.13 Tempus
  • 9.14 Vuno, Inc.
  • 9.15 Zebra Medical Vision, Inc.
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦